Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Mapp Biopharmaceutical / Serum Institute of India

Mapp Biopharmaceutical & Serum Institute of India

2 shared events · Importance 3 · Last updated May 30, 2026

Importance
3
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the NewsDesk Dashboard
Shared Events (2)
59
Tech
WHO Prioritizes Ebola Bundibugyo Treatments
Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.
Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.
May 28, 2026 · 6 articles
27
Accidents
Unknown Event
Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.
Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.
May 18, 2026 · 505 articles
NEWSDESK
Explore this relationship live

Track how Mapp Biopharmaceutical and Serum Institute of India interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.